Amalgamated Bank Eliem Therapeutics, Inc. Transaction History
Amalgamated Bank
- $13.6 Billion
- Q3 2025
Shares
4 transactions
Others Institutions Holding ELYM
# of Institutions
67Shares Held
47.7MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.82% of portfolio
-
Cantor Fitzgerald, L. P. New York, NY2.5MShares$10.3 Million0.01% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.5MShares$6.17 Million1.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.32MShares$5.41 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.04MShares$4.27 Million0.15% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...